临床试验显示,甲型糖尿病患者的美联苯胺将胰岛素需求减少12%,而不会使抗药性恶化。 A clinical trial shows metformin reduces insulin needs in type 1 diabetes patients by 12% without worsening resistance.

澳大利亚新的临床试验发现,传统用于2型糖尿病的Aftformin将1型糖尿病患者的胰岛素需求减少了约12%, A new Australian clinical trial finds metformin, traditionally used for type 2 diabetes, reduces insulin needs by about 12% in people with type 1 diabetes without worsening insulin resistance, according to research published in Nature Communications. 这项研究涉及40名长期患有1型糖尿病的成年人,他们服用甲型素或安慰剂六个月,血糖控制保持. The study involved 40 adults with long-term type 1 diabetes who took metformin or a placebo for six months, with blood sugar control maintained. 虽然该药物的确切机制尚不清楚,但研究人员认为可能涉及肠道微生物。 While the drug’s exact mechanism remains unclear, researchers suggest it may involve gut microbes. 调查结果如果得到证实,可以改善1型糖尿病患者的生活质量,提供低成本、可获得的治疗选择。 The findings, if confirmed, could improve quality of life for type 1 diabetes patients, offering a low-cost, accessible treatment option. 与此同时,另一个研究提出了metformin可能会削弱运动的一些好处,包括血管健康和健身的好处,这表明需要个性化治疗方法. Meanwhile, separate research raises concerns that metformin may blunt some benefits of exercise, including vascular health and fitness gains, suggesting the need for personalized treatment approaches.